Published April 26, 1977 | Version v1
Patent Open

Administration of silver sulfadiazine and radioactive derivatives thereof

Creators

Description

Silver sulfadiazine has been found to be therapeutically useful when administered orally or subcutaneously in doses not exceeding 1,050 mg/kg. It also has been found that radioactive derivatives of silver sulfadiazine localize in tumors, the resultant radiation within the region of the tumor serving to eradicate malignant cells

Availability note (English)

MF available from INIS under the Report Number.

Files

9408062.pdf

Files (309.4 kB)

Name Size Download all
md5:4e524b1c2d8d64416f5f417699b28c19
309.4 kB Preview Download

Additional details

Additional titles

Augmented title (English)
Patent

Publishing Information

Imprint Pagination
8 p.
IPC:
Int. Cl.A61K43/00; A61K31/63.
IPC
Int. Cl.A61K43/00; A61K31/63.
Patent number
US patent document 4,020,150/A/

INIS

Country of Publication
United States
Country of Input or Organization
United States
INIS RN
9408062
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE; S63: RADIATION, THERMAL, AND OTHER ENVIRONMENTAL POLLUTANT EFFECTS ON LIVING ORGANISMS AND BIOLOGICAL MATERIALS;
Descriptors DEI
BIOLOGICAL EFFECTS; MALARIA; MAN; NEOPLASMS; ORAL ADMINISTRATION; RADIOTHERAPY; SILVER; SILVER ISOTOPES; SILVER 111; SUBCUTANEOUS INJECTION; SULFADIAZINE; THERAPY
Descriptors DEC
ANIMALS; ANTIBIOTICS; AZINES; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; DAYS LIVING RADIOISOTOPES; DISEASES; DRUGS; ELEMENTS; HEMIC DISEASES; HETEROCYCLIC COMPOUNDS; INFECTIOUS DISEASES; INJECTION; INTAKE; INTERMEDIATE MASS NUCLEI; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; MAMMALS; MEDICINE; METALS; MINUTES LIVING RADIOISOTOPES; NUCLEI; ODD-EVEN NUCLEI; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANIC SULFUR COMPOUNDS; PRIMATES; PYRIMIDINES; RADIOISOTOPES; TRANSITION ELEMENTS; VERTEBRATES